Literature DB >> 33727891

The Diagnosis Value of a Novel Model with 5 Circulating miRNAs for Liver Fibrosis in Patients with Chronic Hepatitis B.

Qingqing Zhang1, Qidi Zhang2, Binghang Li2, Ying Qu2, Zhenghong Li2, Lungen Lu2, Rongzhou Li1, Xiaobo Cai2.   

Abstract

METHODS: Differential expression of five selected miRNAs (hsa-mir-1225-3p, hsa-mir-1238, hsa-miR-3162-3P, hsa-miR-4721, and hsa-miR-H7) was verified by qRT-PCR in the plasma of 83 patients and 20 healthy controls. The relative expression of these miRNAs was analyzed in different groups to screen target miRNA. A logistic regression analysis was performed to assess factors associated with fibrosis progression. The receiver operating characteristic (ROC) curve and discriminant analyses validated the ability of these predicted variables to discriminate the nonsignificant liver fibrosis group from the significant liver fibrosis group. Furthermore, the established models were compared with other prediction models to evaluate the diagnostic efficiency.
RESULTS: These five tested miRNAs all had signature correlations with hepatic fibrotic level (p < 0.05), and the upregulation trends were consistent with miRNA microarray analysis previously. The multivariate logistic regression analysis identified that a model of five miRNAs (miR-5) had a high diagnostic accuracy in discrimination of different stages of liver fibrosis. The ROC showed that the miR-5 has excellent value in diagnosis of fibrosis, even better than the Forns score, FIB-4, S index, and APRI. GO functions of different miRNAs mainly involved in various biological processes were markedly involved in HBV and revealed signaling pathways dysregulated in liver fibrosis of CHB patients.
CONCLUSIONS: It was validated that the combination of these five miRNAs was a new set of promising molecular diagnostic markers for liver fibrosis. The diagnosis model (miR-5) can distinguish significant and nonsignificant liver fibrosis with high sensitivity and specificity.
Copyright © 2021 Qingqing Zhang et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33727891      PMCID: PMC7939739          DOI: 10.1155/2021/6636947

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  32 in total

1.  Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression.

Authors:  Guanghai Yang; Lin Yang; Wendong Wang; Jiashun Wang; Jianjun Wang; Zhongping Xu
Journal:  Gene       Date:  2015-02-25       Impact factor: 3.688

2.  Circulating microRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients.

Authors:  Mohamed El-Hefny; Shawky Fouad; Tarek Hussein; Rehab Abdel-Hameed; Heba Effat; Haitham Mohamed; Abdel Hady Abdel Wahab
Journal:  J Med Virol       Date:  2018-09-24       Impact factor: 2.327

Review 3.  Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis.

Authors:  Zhong-Hua Lin; Yong-Ning Xin; Quan-Jiang Dong; Qing Wang; Xiang-Jun Jiang; Shu-Hui Zhan; Ying Sun; Shi-Ying Xuan
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

4.  Changes in microRNA expression during disease progression in patients with chronic viral hepatitis.

Authors:  Alessandro Sinigaglia; Enrico Lavezzo; Marta Trevisan; Tiziana Sanavia; Barbara Di Camillo; Elektra Peta; Melania Scarpa; Ignazio Castagliuolo; Maria Guido; Samantha Sarcognato; Rocco Cappellesso; Ambrogio Fassina; Romilda Cardin; Fabio Farinati; Giorgio Palù; Luisa Barzon
Journal:  Liver Int       Date:  2015-01-13       Impact factor: 5.828

5.  Circulating microRNAs as stable blood-based markers for cancer detection.

Authors:  Patrick S Mitchell; Rachael K Parkin; Evan M Kroh; Brian R Fritz; Stacia K Wyman; Era L Pogosova-Agadjanyan; Amelia Peterson; Jennifer Noteboom; Kathy C O'Briant; April Allen; Daniel W Lin; Nicole Urban; Charles W Drescher; Beatrice S Knudsen; Derek L Stirewalt; Robert Gentleman; Robert L Vessella; Peter S Nelson; Daniel B Martin; Muneesh Tewari
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-28       Impact factor: 11.205

6.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Authors:  Xi Chen; Yi Ba; Lijia Ma; Xing Cai; Yuan Yin; Kehui Wang; Jigang Guo; Yujing Zhang; Jiangning Chen; Xing Guo; Qibin Li; Xiaoying Li; Wenjing Wang; Yan Zhang; Jin Wang; Xueyuan Jiang; Yang Xiang; Chen Xu; Pingping Zheng; Juanbin Zhang; Ruiqiang Li; Hongjie Zhang; Xiaobin Shang; Ting Gong; Guang Ning; Jun Wang; Ke Zen; Junfeng Zhang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

7.  Serum levels of tissue inhibitor of metalloproteinase-1 are correlated with liver fibrosis in patients with chronic hepatitis B.

Authors:  Chuan Long Zhu; Wen Ting Li; Yi Li; Ren Tao Gao
Journal:  J Dig Dis       Date:  2012-11       Impact factor: 2.325

Review 8.  Molecular testing in the diagnosis and management of chronic hepatitis B.

Authors:  Alexandra Valsamakis
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

Review 9.  MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma.

Authors:  C Nelson Hayes; Kazuaki Chayama
Journal:  Int J Mol Sci       Date:  2016-02-24       Impact factor: 5.923

10.  The miRFIB-Score: A Serological miRNA-Based Scoring Algorithm for the Diagnosis of Significant Liver Fibrosis.

Authors:  Joeri Lambrecht; Stefaan Verhulst; Hendrik Reynaert; Leo A van Grunsven
Journal:  Cells       Date:  2019-08-29       Impact factor: 6.600

View more
  2 in total

1.  Identification of miRNA-target gene regulatory networks in liver fibrosis based on bioinformatics analysis.

Authors:  Yang Tai; Chong Zhao; Jinhang Gao; Tian Lan; Huan Tong
Journal:  PeerJ       Date:  2021-08-06       Impact factor: 2.984

Review 2.  Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance.

Authors:  Sheng-Han Wang; Shiou-Hwei Yeh; Pei-Jer Chen
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.